Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ado trastuzumab emtansine
Find trials that include:  Any drugs shown
Results 1-16 of 16 for your search:
Start Over
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP FB-10, NCI-2015-00275, NCT02236000
Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positve Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: 15-530, NCI-2016-00505, NCT02657343
Trastuzumab Emtansine or Paclitaxel and Trastuzumab in Treating Patients with Stage I HER2-Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-048, NCI-2013-01818, ML28160, TBCRC 033, NCT01853748
Stereotactic Radiosurgery Followed by HER2 Directed Therapy in Treating Patients with HER2 Positive Breast Cancer with Newly Diagnosed Brain Metastasis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1345GCC, NCI-2015-02007, NCT01924351
A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BO29389, NCI-2014-02389, 2014-001237-83, NCT02289833
Trastuzumab Emtansine and Pertuzumab before Surgery in Treating Patients with HER2-Positive Stage II-III Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-409, NCI-2015-00454, NCT02326974
Trastuzumab Emtansine in Treating Older Patients with Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: RU011301I, NCI-2015-00468, NCT02414646
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4529g, NCI-2009-01154, BO25430, NCT00781612
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TDM4884g, NCI-2011-03406, NCT01120561
Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-335, NCI-2016-00262, NCT02675829
Ado-Trastuzumab Emtansine in Treating Patients with HER2-Positive Metastatic or Locally Advanced Breast Cancer that Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7900, NCI-2013-00552, CC-7900, NCT01816035
Palbociclib Isethionate and Ado-Trastuzumab Emtansine in Treating Patients with Recurrent or Metastatic HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-05113, NCI-2014-00821, 042013-042, 8843, Mod13_STU 042013-042, Mod9_STU 042013-042, NCT01976169
Taselisib and Anti-HER2 Therapy in Treating Patients with Advanced HER2+ Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-024, NCI-2015-00627, ML29407, NCT02390427
Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29831, NCI-2015-02225, 2015-002113-29, NCT02605915
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment with Ado-Trastuzumab Emtansine in Patients with Metastatic HER2 Positive Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14099, NCI-2014-01812, 108543, 114291, 117437, NCT02226276
Start Over